Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...

AN2 Therapeutics said it was planning to meet with the U.S. Food and Drug Administration to discuss a development path for epetraborole, a treatment of non-tuberculous mycobacterial lung disease. The ...

Details about company presentations, webcasts, and other events can be found on the“Investors” section of Xenon's website. When available, webcasts will be posted for replay following the event. The ...

Net income of $1.5 millionAdjusted EBITDA1 of $1.9 millionADHD Portfolio net revenue up 1% to $15.3 millionPediatric Portfolio net revenue up 54% sequentially$20.1 million cash balance at September 30 ...

The group was led by Casdin Capital, which surged 16 percent last month, according to an investor. This puts its share class that invests only in public securities up more than 40 percent for the year ...

Tempest Therapeutics (TPST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good afternoon, and thank you for standing by. At this time, I’d ...